The May 14,2018 Corporate Update is very interesting. Of course a BO could occur at any time. However, a series of regional deals would move the share price dramatically. Here are some parts of the Corporate Update the struck me.
"We continue discussions with outside partners that address the commercial potential of Ampion™ in multiple world markets....
Regulatory Exclusivity and IP protection:
The Company believes that Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, will be identified as a “reference product” upon FDA approval of their BLA. Reference products are granted 12 years of exclusivity under the PHS Act, 42 U.S.C. § 262(k)(7). Specifically, FDA is not permitted to approve an application for a biosimilar or interchangeable product until 12 years after the date of the first licensure of the reference product.
The existing Ampion™ portfolio has patent coverage in all major jurisdictions throughout the world (U.S., Europe, Australia, Brazil, Canada, China, Eurasia, Hong Kong, India, Indonesia, Israel, Japan, Korea, Mexico, Malaysia, New Zealand, Philippines, Singapore, South Africa) for pharmaceutical compositions and methods of treating a range of conditions. The portfolio includes 125 issued patents and 85 pending applications throughout seven primary patent families having expiration dates that extend to 2035."
There could be many regional deals with upfront and sales related escalating double digit royalties IMO. The patent portfolio is TRULY world wide!
"The refusal of the real is the number one dogma of our time" Rene Girard
